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Asthma in older adults aﬀects quality of life and results in a higher hospitalization rate and mortality. In common clinical
practice, asthma in the elderly is underdiagnosed and undertreated or overdiagnosed and mistreated. The age-related reduction
in perception of shortness of breath and the high incidence of comorbidities make the diagnosis and management more diﬃcult
and challenging for the physicians. Chronic obstructive pulmonary disease (COPD) is usually easy to distinguish from asthma,
but sometimes the distinction from late-onset asthma in older patients, particularly in cigarette smokers, is diﬃcult and may be
impossible. Both diseases are characterized by the presence of airﬂow obstruction but have distinct pathogenesis, inﬂammatory





The increasing burden of obstructive lung diseases, such
as Asthma and Chronic Obstructive Pulmonary Disease
(COPD), appears to be caused, at least in part, by the ageing
of the world’s population [1]. The World Health Organiza-
tion estimates that between the years 2000 and 2050, the
proportion of persons over 65 years of age is expected to
represent up to 17% of the total world population [1]. In
the case of asthma, the prevalence in the elderly is also
high, aﬀecting >10% of patients >60 years of age, while the
estimated prevalence for COPD represents a 20% to 30% in
patients >70 years of age [2, 3].
Although it was believed that asthma is predominantly a
childhood disease [4, 5], asthma in the elderly is not a rare
disorder [6]. Moreover, it is frequently underdiagnosed or
misdiagnosed [4, 5] due to atypical presentation, age-related
reduction of dyspnea perception, and associated comorbidi-
ties [6, 7].
In particular, Asthma and COPD may overlap and con-
verge in older people [6, 8]. Ageing is associated with unique
issues that modify expression, recognition, and treatment of
the disease [6, 7]. Many older adults with asthma have a
persistent airway obstruction on pulmonary function testing
which makes it diﬃcult to diﬀerentiate asthma from COPD
[8–11]. Both diseases are associated with similar symptoms
such as shortness of breath, wheezing, and coughing with or
without sputum production [6, 8]. Furthermore, to distin-
guish COPD from late-onset asthma, particularly in elderly
smokers, often remains a challenge for the clinician [6, 8].
For example, a longitudinal study found that 16% of patients
with asthma developed features consistent with irreversible
airﬂow obstruction after 20 to 30 years of followup [9].
Nevertheless, Asthma and COPD are two quite diﬀerent
and independent diseases with diﬀerent pathogenesis, diﬀer-
ent pathology, diﬀerent type of inﬂammation, and diﬀerent
prognosis [8]( Table 1). Asthma traditionally characterized
by an eosinophilic inﬂammation aﬀects all the airways but
not lung parenchyma, and it is linked to airway hyper-
responsiveness [4, 5]. The airﬂow obstruction in asthma
is often reversible spontaneously or with treatment [4, 5].
On the other hand, COPD refers to a disorder in which
airﬂow limitation is not fully reversible [12]. The airﬂow
obstruction is caused by damage to the small airways as2 Journal of Allergy
a result of airway inﬂammation (predominantly neutro-
philic), structural changes in small and large airways
(remodelling), and parenchymal destruction as a result of
loss of alveolar attachments and decrease in elastic recoil
(emphysema) [8, 12]. Although the clinical features of these
diseases help us to diﬀerentiate between them in most
patients, the spectrum of obstructive lung diseases seen in
clinical practice is more complex, particularly, among the
elderly, who may have components of both diseases [8].
The aim of this paper is to highlight the main and more




Elderly patients with suspected asthma require a systematic
approach to their diagnosis [13, 14]. Older patients with
asthma underestimate the severity or signiﬁcance of their
symptoms, attribute symptoms to other causes such as age-
ing, COPD, or cardiac failure, or ignore symptoms entirely.
For example, breathlessness, a common symptom aﬀecting
up to a third of older people, often is perceived to be part
of the normal process of ageing [13–15]. Self-limitation of
activities, social isolation, and depression further contribute
to underdiagnosis of asthma in older adults [15]. The
condition that presents the greatest diagnostic confusion for
asthma among older persons is COPD [13, 14].
Although asthma and COPD share symptoms, their
presentation is typically diﬀerent [4, 5, 12]. Symptoms such
as wheezing, breathlessness, chest tightness, and coughing
should be carefully evaluated. Older persons with COPD
often experience breathlessness when they exert moderate or
even minimal physical eﬀorts. On the contrary, breathless-
ness in asthma usually occurs in exacerbations [11, 13].
Coughing, which can be the only presenting symptom
among older persons with asthma, is also associated with an
exacerbation, while it occurs regularly with COPD [11, 13].
Conversely, the diﬀerentiation of symptoms is not always
as straightforward as the above examples. Wheezing, the
most common symptom of asthma in the elderly [13, 14],
can be also attributed to other pathological conditions such
as COPD, cardiac failure, acute bronchitis, bronchiectasis,
gastroesophageal reﬂux, aspiration or inhalation of foreign
body, and tracheobronchial tumors [10, 11, 16]. Breathless-
ness is usually perceived as part of the normal process of
ageing. Clinicians have to rule out other diseases such as
COPD, congestive heart failure, pulmonary embolism, hy-
perventilation/panic disorder, Churg-Strauss syndrome, and
other vasculitis [10, 11].
3. Spirometry,Pulmonary FunctionTests and
Bronchial Hyperresponsiveness(BHR)
Pulmonarytestingwithbronchodilatorshasbeenusedtodif-
ferentiate asthma from COPD, with COPD obtaining a lesser
response [4, 5, 12]. A ﬁnal diagnosis of asthma is determined
when either clinic spirometry or pulmonary function tests
demonstrate airﬂow obstruction that improves signiﬁcantly,
deﬁned as both a 12% and 200mL improvement in forced
expiratory volume in one second (FEV1) in response to
inhaled bronchodilator [4, 5]. However, previous studies
demonstrated that an increase ≥10% of the predicted FEV1
after inhalation of a short-acting bronchodilator may have a
higher likelihood of distinguishing asthmatics from COPD
patients [17]. To further confuse the distinction between
asthma and COPD, a recent study with over 5000 COPD
patients found that more than two-thirds showed meaning-
ful increases in lung function following administration of
bronchodilators [18].
Nonetheless spirometry, before and after bronchodila-
tion, should be performed although it may have some ad-
ditional diﬃculties in the elderly. Several studies reported
that spirometry can be adequately done in the majority of
older patients when the staﬀ is properly trained and with
the appropriate application of reference values in this age
group [16, 17]. The American Thoracic Society/European
Respiratory Society pulmonary function test interpretation
guidelines recommend that the lower limit of the normal
range for FEV1/FVC ratio, based on the ﬁfth percentile cor-
rected for age, sex, height, and race, be used to detect airﬂow
obstruction [17].
The ﬁxed airﬂow limitation of most patients can be
deﬁned as a postbronchodilator FEV1 of <80% pred (in the
presence of a reduced FEV1/FVC) after a 7-to-14 day course
of oral corticosteroids (40mg per day for adults) [19]. A
negative response may indicate COPD or rarely refractory
asthma (corticosteroid resistant) [20, 21]. Population studies
haveshownthatasmanyas30%ofpatientswithﬁxedairﬂow
obstruction have a past history of asthma [22].
Often times there is a need for more tests such as
lung volumes (total lung capacity (TLC), functional residual
capacity (FRC), residual volume (RV), RV/TLC%), or diﬀus-
ing capacity (DLCO) of the lung. Lung volumes are elevated
in COPD [12]. The presence of a normal diﬀusing capacity
for carbon monoxide (DLCO) can be useful to diﬀerentiate
patientswithasthmafrompatientswithCOPD;nevertheless,
patients with asthma and a history of smoking may also
present a reduced DLCO [16, 21]. Generally, the decreased
DLCO may be directly related to the loss of alveolar-capillary
surface area that is associated with emphysema [12, 17, 21].
Bronchial hyperresponsiveness (BHR) has long been
considered a diﬀerentiating feature of asthma [4, 5]. The
role of BHR in the elderly is a matter of debate. Scichilone
et al. in a review of eighteen studies showed a positive
association between age and airway hyperresponsiveness,
the prevalence of which appears to increase in the elderly
[23]. The most important determinants were reduced lung
function, probably due to geometric factors, and a history
of smoking. Atopy, female sex, inﬂammatory, and neuronal
mechanisms should also be considered as determinants of
airway hyperresponsiveness in the elderly [23].
Likewise, early detection of airway hyperresponsiveness
in these individuals could permit the identiﬁcation of
elderly asthmatics at an earlier stage so as to optimize the
treatment of this disease [23, 24]. However, the physician
needs to be alert during BHR tests since the airways ofJournal of Allergy 3
elderly patients with asthma are more reactive than those of
young asthmatics when airway responsiveness is expressed in
terms of methacholine-induced changes in FVC [25]. This
implies that elderly asthmatic patients are at higher risk of
airway closure. Furthermore, elderly individuals experience
less awareness of bronchoconstriction during methacholine
bronchoprovocation, despite similar degrees of bronchocon-
striction.Thepresenceofoneormoreco-morbidconditions,
which become common in the elderly, signiﬁcantly impair
perception of bronchoconstriction, and the condition of
unrecognised airway hyperresponsiveness could lead to the
occurrence of severe airway narrowing [14–16].
The role of BHR as a risk factor for obstructive lung
diseases in the elderly has not been well studied, although
reports have shown that airway hyperresponsiveness may be
more common than previously thought among older adults
[26, 27]. In COPD patients, the Lung Health Study found
BHR to methacholine in 63% of men and 87% of women
[26]. The authors stated the hypothesis that an important
determinant of BHR is gender diﬀerences in airway caliber
andsmoking.Inconclusion,measuringBHRmightbeuseful
also in patients with COPD. However, to establish these
methods in clinical routine in COPD patients, more data are
clearly needed [27].
4. StructuralChanges
Asthma in an older adult is the result either of childhood
asthma that is long-lasting, or late-onset disease [28]. Age-
relatedchangesleadtoincreasedairtrappingandareduction
in chest wall compliance. Degenerative changes in muscles
cause reduced force generation capacity of the respiratory
muscles and an increased work of breathing [6, 10, 11, 29].
In general, asthma in older adults is characterized by less
IgE-mediated processes and more frequently by irreversible
airway obstruction. An accelerated decline in lung function
occurs in elderly asthmatics, mainly due to airway remod-
elling,especiallyinthesmallairwaysfrominﬂammationthat
characterizes asthma [28, 29]. Compared with the general
population, elderly asthmatics are more likely to die of lung
diseases, presumably due to respiratory tract infections, es-
pecially those with poor socio-economic status [29, 30].
In detail, airﬂow obstruction in asthma is the results of
a serial of structural changes of the airway lumen rather
than changes in lung parenchyma [31–33]. The CD4+ Th2
lymphocytes may have important role in maintaining this
speciﬁc asthmatic airway inﬂammatory cascade [31–33].
Chronic inﬂammation in asthma results in bronchial re-
modelling characterized by basement membrane thickening,
mucosalbloodvesselsproliferation,extracellularmatrixpro-
teins deposition, mucus gland stimulation, smooth muscle
cell and myoﬁbroblast proliferation, and ﬁnally defective
epithelium regeneration and atrophy [31–33]. While some
of these changes may be reversible with treatment, at some
point, they may become permanent causing ﬁxed airway
obstruction. In elderly asthmatics the presence of emphyse-
ma is minimal, and airway remodeling is thought to be the
m a i nc a u s eo fﬁ x e da i r ﬂ o wo b s t r u c t i o n[ 31–33].
On the contrary, in COPD it seems that ﬁxed airway
obstruction is the ﬁnal result of structural changes of periph-
eral airways and the lung parenchyma [31–33]. Inﬁltration
of the airways with neutrophils and CD8(+)l y m p h o c y t e s
in COPD is associated with airway remodeling, mucous
plugging, smooth muscle hypertrophy, and airway wall
ﬁbrosis [31–33], (Table 1). In COPD, the remodeling of the
small airways and lung parenchyma are the main correlates
tothelimitationofexpiratoryairﬂow[32–35].Thickeningof
the airway wall, goblet cell hyperplasia, mucous gland hyper-
trophy, and the luminal obstruction caused by inﬂammatory
exudates and mucous are features of COPD. Squamous
epithelial metaplasia and airway wall ﬁbrosis are commonly
observed characteristics of COPD [32–35]. Destruction and
ﬁbrosis of the alveolar walloccur in COPD but not in asthma
[32–35].
Recently, High-resolution CT scan (HRCT) has been pro-
posed as an additional tool to assess pulmonary structural
changes in long-standing diseases, such as asthma and
COPD.Moreover,bydiﬀerentiatingairwayremodellingfrom
parenchymal alterations, HRCT imaging could contribute
towards distinguishing between asthma and COPD [36,
37]. Anatomical pulmonary changes, including bronchial
wall thickening, emphysema, and bronchiectasis, have been
demonstratedbyHRCTscaninsomestudies[36–38].HRCT
scan has been previously used to quantify abnormalities
of the airways due to airway remodeling, and it has been
found that the HRCT scan score correlated with the severity
of asthma and airﬂow obstruction [36–38]. However, there
are no studies so far evaluating speciﬁcally abnormalities
in lung CT of elderly asthmatics. In a recent study [39],
it was assessed whether airway remodelling is restricted to
speciﬁc subphenotypes of severe asthma. Patients included
werebetween43–54yearsold,andtheresultsshowedthatthe
degree of airway wall remodelling assessed by CT scanning
was similar in all severe asthma subphenotypes and was
associated with airﬂow limitation and neutrophilic inﬂam-
mation [39]. To summarize, the above studies demonstrated
a close relationship between HRCT scan alterations and the
extent of in vivo remodelling occurring in the airways of
patients with obstructive airway diseases. The use of high-
resolution computed tomography imaging could contribute
to diﬀerential diagnosis between asthma and COPD.
Lately, high-dimensional biological techniques (e.g., ge-
nomics,metabolomics)allowassessmentofdiseasebiomark-
er proﬁles [40]. This provides opportunities to discriminate
disease entities based on composite molecular signatures.
This may not only be applicable to serum or bronchoalveolar
lavage ﬂuid but also to noninvasive alternatives such as
exhaled air and sputum [40, 41]. Exhaled air is known to
contain thousands of volatile organic compounds (VOCs)
that are derived from various metabolic and inﬂammatory
pathways in the lung [41]. Fens et al. [41] showed that
“breathprints” from patients with asthma were diﬀerent
from patients with COPD (accuracy 96%), from nonsmok-
ingcontrolsubjects,andfromsmokingcontrolsubjects[41].
Furthermore, induced sputum is an extensively used
noninvasive method that can serve as a window to assess
the microenvironment of the lungs. The ﬁrst studies that4 Journal of Allergy
Table 1: Main diﬀerences between COPD and Asthma.
COPD Asthma
Onset Mid life Early or Late onset
Risk factors Smoking Atopy, irritant exposures, smoking
Symptoms Slowly progressive Intermittent
(i) Breathlessness On moderate/minimal eﬀort On exacerbations
(ii) Cough Regularly On exacerbations
Family history May be present May be present
FEV1/FVC ratio <70% <70%
FEV1% predicted <80% <80%




CD8+ cells (Tc) Mast cells
CD4+ cells (Th2)
Structural changes
Airway smooth muscle + Airway smooth muscle +++
Peripheral airways All airways
Parenchymal destruction No parenchymal involvement
Epithelial metaplasia Epithelial shedding
Fibrosis++
(peribronchiolar) Fibrosis + (subepithelial)
Mucus secretion +++ Mucus secretion +
Steroid response +/− +++
revealed somatic mutations in the form of Microsatellite
DNA Instability (MI), in sputum cells, were in COPD [42,
43] and later on in Asthma [44]. However, in a comparative
study between COPD and Asthma at the microsatellite DNA
level, COPD patients revealed higher frequency of somatic
mutations when compared with asthmatics [45]. In the
same study COPD speciﬁc microsatellite sites were identiﬁed
adjacent to genes related to COPD pathogenesis (e.g.,
Surfactant A, Perforin, CD8, Tumor Necrosis Factor (TNF)).
In a recent study Dima et al. [46] found that COPD patients
had increased sputum neutrophils, Interleukin-8, and TNF-
α levels compared to smoking asthmatics [46]. Sputum
neutrophilia was inversely correlated with the change in
FEV1 in smoking asthmatic patients while no correlation
was found between BHR and inﬂammation in asthmatic
patients, regardless of smoking. Reversibility was not cor-
related with inﬂammation in COPD patients. However, the
response to adenosine 5 monophosphate (AMP) challenge
was correlated with sputum neutrophils, concluding that the
combination of lung function testing, sputum induction,
and BHR reveals information that facilitates the distinction
between these diseases [46].
5. Immunosenescence andObstructive
LungDiseases
The ageing process aﬀects the innate and adaptive im-
mune processes, irrespective of the presence of disease, by
a phenomenon known as immunosenescence. Neutrophilic
inﬂammation, similar to that noted in COPD and severe
noneosinophilic asthma, is present in the airways of older
people,asaresultofthelifelongantigenicandenvironmental
exposure and age-related changes to innate immunity [47].
Studies in older asthmatics have shown age-related chan-
ges in innate immunity including lung epithelial cell senes-
cence, increased airway neutrophilia, decreased eosinophil
function, decreased levels of cytotoxic natural killer (NK)
cells and macrophages [48, 49]. Age-related changes in adap-
tive immunity include decreased dendritic cell function and
a chronic proinﬂammatory state characterized by increased
levels of Inteleukin-1, Interleukin-6, and TNF-α [48, 49].
Studies showing a decrease in Interferon-g/Interleukin-4 and
Interferon-g/Interleukin-10 after stimulation of NK T cells
in older asthmatics support the notion of a transition to a
greater T-helper type 2 (Th2) responses with aging [48–50].
Ontheotherhand,agingandCOPDarecharacterizedby
increases in proinﬂammatory cytokines such as interleukin
Interleukin-6 and TNF-α, which are implicated in aging-
related inﬂammatory diseases and correlate with degree
of obstruction in COPD [51]. There is an age-dependent
decline in naive T cells with oligoclonal expansion of CD8(+)
CD28null T cells from chronic antigenic stimulation, leading
to a decline in adaptive immune response. To compensate
for this decline there is a paradoxical upregulation of
innate immune system resulting in a proinﬂammatory state
[51]. The dysregulated immune system associated with
aging results in recruitment and retention of neutrophils,
macrophages, and CD4(+) and CD8(+) T cells in the lungs
of smokers with COPD [51, 52]. Such changes may lead toJournal of Allergy 5
persistent presence of neutrophils in lungs, which in turn
may cause emphysematous destruction via exaggerated re-
lease of neutrophil elastase. Cigarette smoke may further
contribute to epithelial injury by inducing recruitment of
neutrophils and macrophages to the lungs, and such cells in
the elderly seem to be activated in uncontrolled and patho-
logical ways, releasing more proinﬂammatory cytokines and
amplifying a cascade of ongoing inﬂammation and paren-
chymal lung damage [51–53].
Asaﬁnalpoint,changesinthelungthatoccurwithaging
often mimic those seen in COPD. Furthermore, immunose-
nescence is strongly associated with persistently activated in-
nateimmunityandpossiblyuncontrolledadaptiveimmunity
thus, becoming even more diﬃcult to diﬀerentiate asthma
from COPD in the elderly population.
6.AllergyandAtopy
Indoor allergen exposure and sensitization are very common
in childhood asthma. The prevalence of atopy has been con-
sidered to be uncommon in elderly population with asthma
[54]. Recent studies suggest that although the prevalence of
atopy may be inferior in the elderly, compared with young
population, older adults may have a higher incidence of
allergen sensitization than previously believed [54].
It is a matter of debate, however, if allergen exposure and
sensitizationplaythesameroleinthedevelopmentofasthma
in adults as they do in children. Reports from a recent study
by Sin et al. [21] observed a higher prevalence of atopy in
elderly asthmatic patients when compared with age-matched
controls without asthma. Thus, a positive skin test was
revealed in 37% of asthmatic versus 8.3% of COPD patients,
while asthmatics had also higher serum total IgE levels
compared to COPD patients [21]. Furthermore, previous
studies reported an increased incidence of allergic history
in asthmatics, starting at age 65 or over [24]. Although the
mean size of common allergens was greater in asthmatics,
Sitkauskiene et al. [55] did not ﬁnd any diﬀerence in positive
skin test response between asthmatics and COPD patients,
buta signiﬁcantly raised serumtotal IgE level wasdetected in
the asthmatic patients [55]. In another study, Huss et al. [54]
showed a positive skin test in 74.6% of elderly asthmatics.
The results from another study in the elderly population
revealed that the presence of cockroach-speciﬁc serum IgE
was associated with more severe asthma in elderly patients,
with increased airway obstruction and hyperinﬂation [56].
Although available data seem to favor the decline of
allergen sensitization with age, the prevalence of allergic
sensitizations in the elderly population with respiratory
symptoms is substantial enough to warrant evaluation of the
atopic condition. This approach will improve diagnosis and
could allow better disease management leading to signiﬁcant
reduction in asthma morbidity [24].
7. Conclusions
In clinical practice, the diﬀerentiation between Asthma and
COPD is often diﬃcult to achieve. Especially in elderly
patients with long-term asthma, reversibility of airway ob-
struction is diminished, and a disease pattern similar to
COPD may develop. In addition, smoking and ageingin-
creases BHR. Furthermore, the neutrophils are increased,
resulting in asthmatics with a COPD phenotype.
On the other hand, although it is known that COPD is
characterized by chronic airﬂow limitation that is not fully
reversible, there is a subgroup of COPD patients with re-
versibility, which has been associated with increased exhaled
nitric oxide and sputum eosinophilia. COPD is often accom-
panied by BHR, and smoking as well as ageing seems to be
risk factors for increasing BHR whereas smoking cessation
improves BHR, both in asthma and COPD patients.
The combination of lung function testing, BHR and ato-
py status, HRCT scans, and the newly developed biological
techniques, allowing the assessment of biomarker proﬁles,
could facilitate the distinction between these diseases.
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